Celgene (CELG) Provides Update on Topline Data from GED-0301 in Active Crohn’s Disease; No New Safety Issues Found
Tweet Send to a Friend
Celgene Corporation (Nasdaq: CELG) announced interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
